Evidence map›Paper›PMID 36482186›Full record

ArticleBritish journal of cancer2023

Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma.

Otilia Kimpel, Paul Schindler, Laura Schmidt-Pennington, Barbara Altieri, Felix Megerle, Harm Haak, James Pittaway, Ulrich Dischinger, Marcus Quinkler, Knut Mai and 3 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00453674 (Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00453674 recruitingnot on this map

Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry

TypeobservationalSponsorUniversity of WuerzburgRan2003 to 2030Enrolled1,000ConditionsAdrenocortical Carcinoma
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Contemporary Approaches to Adrenocortical Carcinoma.Hematology/oncology clinics of North America · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Adrenocortical Cancer Cell uptake of Iron Oxide Nanoparticles.bioRxiv : the preprint server for biology · 2024
    Article
  12. Article
  13. Current Evidence on Local Therapies in Advanced Adrenocortical Carcinoma.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2024
    Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Otilia KimpelDivision of Endocrinology and Diabetes, Department of Medicine, University Hospital, University of Würzburg, Würzburg, Germany.
Paul SchindlerDivision of Endocrinology and Diabetes, Department of Medicine, University Hospital, University of Würzburg, Würzburg, Germany.
Laura Schmidt-PenningtonDepartment of Endocrinology & Metabolism, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.ORCID http://orcid.org/0000-0001-9990-6387
Barbara AltieriDivision of Endocrinology and Diabetes, Department of Medicine, University Hospital, University of Würzburg, Würzburg, Germany.
Felix MegerleDivision of Endocrinology and Diabetes, Department of Medicine, University Hospital, University of Würzburg, Würzburg, Germany.
Harm HaakDepartment of Internal Medicine, Máxima MC, Eindhoven/Veldhoven The Netherlands. Maastricht University, CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht, the Netherlands. Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Centre+, Maastricht, the Netherlands.
James PittawayCentre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Ulrich DischingerDivision of Endocrinology and Diabetes, Department of Medicine, University Hospital, University of Würzburg, Würzburg, Germany.
Marcus QuinklerDepartment of Endocrinology & Metabolism, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
Knut MaiDepartment of Endocrinology & Metabolism, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117, Berlin, Germany.
Matthias KroissDivision of Endocrinology and Diabetes, Department of Medicine, University Hospital, University of Würzburg, Würzburg, Germany.
Bülent Polat *Department of Radiation Oncology, University Hospital, University of Würzburg, Würzburg, Germany.
Martin Fassnacht *Division of Endocrinology and Diabetes, Department of Medicine, University Hospital, University of Würzburg, Würzburg, Germany. Fassnacht_m@ukw.de.ORCID http://orcid.org/0000-0001-6170-6398
University of Würzburg · DEHumboldt-Universität zu Berlin · DEMaastricht University Medical Centre · NLQueen Mary University of London · GB

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 314061271Medical Research Council MR/S022155/1
6 · The paper itself

Abstract

backgroundInternational guidelines emphasise the role of radiotherapy (RT) for the management of advanced adrenocortical carcinoma (ACC). However, the evidence for this recommendation is very low.

methodsWe retrospectively analysed all patients who received RT for advanced ACC in five European centres since 2000. PRIMARY ENDPOINT: time to progression of the treated lesion (tTTP). Secondary endpoints: best objective response, progression-free survival (PFS), overall survival (OS), adverse events, and the establishment of predictive factors by Cox analyses.

resultsIn total, 132 tumoural lesions of 80 patients were treated with conventional RT (cRT) of 50-60 Gy (n = 20) or 20-49 Gy (n = 69), stereotactic body RT of 35-50 Gy (SBRT) (n = 36), or brachytherapy of 12-25 Gy (BT) (n = 7). Best objective lesional response was complete (n = 6), partial (n = 52), stable disease (n = 60), progressive disease (n = 14). Median tTTP was 7.6 months (1.0-148.6). In comparison to cRT

conclusionsThis largest published study on RT in advanced ACC provides clear evidence that RT is effective in ACC.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaBrachytherapyRadiosurgeryHumansProgression-Free SurvivalRetrospective Studies

Identifiers

PMID36482186
PMCPMC9938283
OpenAlexW4310965674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.